Gene · 92521
Papers3,158
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,141 to 1,160 of 3,158
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Efficacy of a multiple-indication antiviral herbal drug (Saliravira®) for COVID-19 outpatients: A pre-clinical and randomized clinical trial study. | Biomed Pharmacother | 2022 | 35276467 | PubTator, text mining | PubMed |
| Antisense technology as a potential strategy for the treatment of coronaviruses infection: With focus on COVID-19. | IET Nanobiotechnol | 2022 | 35274474 | PubTator, text mining | PubMed |
| SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines. | Front Med (Lausanne) | 2022 | 35273977 | PubTator, text mining | PubMed |
| OpenCell: Endogenous tagging for the cartography of human cellular organization. | Science | 2022 | 35271311 | PubTator, text mining | PubMed |
| Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia. | Cancers (Basel) | 2022 | 35267643 | PubTator, text mining | PubMed |
| SARS-CoV-2 reinfection prevents acute respiratory disease in Syrian hamsters but not replication in the upper respiratory tract. | Cell Rep | 2022 | 35263638 | PubTator, text mining | PubMed |
| Design and various in silico studies of the novel curcumin derivatives as potential candidates against COVID-19 -associated main enzymes. | Comput Biol Chem | 2022 | 35259661 | PubTator, text mining | PubMed |
| Inhibition of SARS-CoV-2 replication by zinc gluconate in combination with hinokitiol. | J Inorg Biochem | 2022 | 35255411 | PubTator, text mining | PubMed |
| An Enhanced Hybrid Screening Approach to Identify Potent Inhibitors for the SARS-CoV-2 Main Protease From the NCI Compound Library. | Front Chem | 2022 | 35252116 | PubTator, text mining | PubMed |
| Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies. | Front Pharmacol | 2022 | 35250581 | PubTator, text mining | PubMed |
| In silico evaluation of Vitis amurensis Rupr. Polyphenol compounds for their inhibition potency against COVID-19 main enzymes Mpro and RdRp. | Saudi Pharm J | 2022 | 35250347 | PubTator, text mining | PubMed |
| Emerging small molecule antivirals may fit neatly into COVID-19 treatment. | Drugs Ther Perspect | 2022 | 35250258 | PubTator, text mining | PubMed |
| Whole genome analysis of rotavirus strains circulating in Benin before vaccine introduction, 2016-2018. | Virus Res | 2022 | 35247484 | PubTator, text mining | PubMed |
| Comparative Genomics and Characterization of SARS-CoV-2 P.1 (Gamma) Variant of Concern From Amazonas, Brazil. | Front Med (Lausanne) | 2022 | 35242782 | PubTator, text mining | PubMed |
| Role of Dexamethasone and Methylprednisolone Corticosteroids in Coronavirus Disease 2019 Hospitalized Patients: A Review. | Front Microbiol | 2022 | 35242118 | PubTator, text mining | PubMed |
| Aptamers as promising nanotheranostic tools in the COVID-19 pandemic era. | Wiley Interdiscip Rev Nanomed Nanobiotechnol | 2022 | 35238490 | PubTator, text mining | PubMed |
| Integrated Multi-Omics Analysis Reveals the Effect of Maternal Gestational Diabetes on Fetal Mouse Hippocampi. | Front Cell Dev Biol | 2022 | 35237591 | PubTator, text mining | PubMed |
| Modulation of Innate Antiviral Immune Response by Porcine Enteric Coronavirus. | Front Microbiol | 2022 | 35237253 | PubTator, text mining | PubMed |
| The vital role of animal, marine, and microbial natural products against COVID-19. | Pharm Biol | 2022 | 35234563 | PubTator, text mining | PubMed |
| In-silico genomic landscape characterization and evolution of SARS-CoV-2 variants isolated in India shows significant drift with high frequency of mutations. | Saudi J Biol Sci | 2022 | 35233173 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/92521/papers?page=58